SynthesisJournal of neurology2026
Brivaracetam for status epilepticus: a systematic review.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStatus epilepticus (SE) is a neurological emergency characterized by prolonged or recurrent seizures leading to secondary brain injury, morbidity and mortality. Timely and aggressive management is essential to mitigate these negative effects. Brivaracetam (BRV), a novel antiseizure medication, has emerged as a potential treatment option for SE, but its efficacy and safety profile remain inadequately characterized.
objectiveThis systematic review aims to evaluate the available evidence regarding the administration, effectiveness, and safety of BRV in the management of SE, refractory status epilepticus (RSE), and super-refractory status epilepticus (SRSE).
methodsPRISMA guidelines were followed. A literature search was conducted across MEDLINE, EMBASE, CINAHL and Cochrane CENTRAL. Original research involving adult patients with SE treated with BRV was included and quality assessed. Data on patient demographics, treatment protocols and outcomes were extracted.
resultsA total of 12 studies encompassing 263 patients suffering from SE, RSE, and SRSE were included. Patients suffered from both generalized and focal seizures with or without prominent motor features due to various etiologies. Eighty-two patients received levetiracetam prior to BRV. The overall seizure cessation rate following BRV administration was 56%, predominantly within 72 h. The timing of BRV initiation was variable, with intravenous loading doses ranging from 50 to 400 mg, followed by maintenance doses of 80-400 mg per day, administered every 8-12 h enterally. Adverse events were reported in nine studies, with drowsiness and psychiatric effects being the most common.
conclusionBRV may be an effective treatment for SE, RSE, and SRSE, demonstrating efficacy across various seizure semiologies and etiologies, although there are substantial limitations within the available literature.
Indexed as
Identifiers
41838218What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.